Investigators have explored the potential of KRAS inhibition in patients with colorectal cancer (CRC), and early results have established the pathway as a prime target for drug development.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045